GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » InspireMD Inc (NAS:NSPR) » Definitions » Return-on-Tangible-Equity

InspireMD (InspireMD) Return-on-Tangible-Equity : -52.25% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is InspireMD Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. InspireMD's annualized net income for the quarter that ended in Dec. 2023 was $-21.62 Mil. InspireMD's average shareholder tangible equity for the quarter that ended in Dec. 2023 was $41.38 Mil. Therefore, InspireMD's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 was -52.25%.

The historical rank and industry rank for InspireMD's Return-on-Tangible-Equity or its related term are showing as below:

NSPR' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1539.76   Med: -126.02   Max: -62.09
Current: -62.09

During the past 13 years, InspireMD's highest Return-on-Tangible-Equity was -62.09%. The lowest was -1,539.76%. And the median was -126.02%.

NSPR's Return-on-Tangible-Equity is ranked worse than
76.92% of 767 companies
in the Medical Devices & Instruments industry
Industry Median: 2.07 vs NSPR: -62.09

InspireMD Return-on-Tangible-Equity Historical Data

The historical data trend for InspireMD's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InspireMD Return-on-Tangible-Equity Chart

InspireMD Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -141.95 -120.19 -65.29 -72.62 -70.01

InspireMD Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -98.72 -110.48 -67.42 -45.99 -52.25

Competitive Comparison of InspireMD's Return-on-Tangible-Equity

For the Medical Devices subindustry, InspireMD's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InspireMD's Return-on-Tangible-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where InspireMD's Return-on-Tangible-Equity falls into.



InspireMD Return-on-Tangible-Equity Calculation

InspireMD's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-19.916/( (17.393+39.501 )/ 2 )
=-19.916/28.447
=-70.01 %

InspireMD's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-21.62/( (43.257+39.501)/ 2 )
=-21.62/41.379
=-52.25 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


InspireMD  (NAS:NSPR) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


InspireMD Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of InspireMD's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


InspireMD (InspireMD) Business Description

Traded in Other Exchanges
N/A
Address
4 Menorat Hamaor Street, Tel Aviv, ISR, 6744832
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Germany, Italy, Belarus, Brazil, and other countries.
Executives
Gary S Roubin director 4300 ROCKMORE RD JACKSON, WYOMING WY 83001
Patrick Verta officer: EVP Clinical/Medical Affairs 12988 VALLEY VIEW ROAD, EDEN PRAIRIE MN 55344
Michael Berman director 735 PALAMAR AVENUE, SUNNYVALE CA 94085
Thomas J Kester director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Paul Stuka director C/O OSIRIS PARTNERS, LLC, ONE LIBERTY SQUARE, 5TH FLOOR, BOSTON MA 02109
Andrea Tommasoli officer: Chief Operating Officer 22, RUE DE LA PLAGE, COLLONGES AU MONT D OR I0 69660
Shane Thomas Gleason officer: VP Global Marketing 18 NORTHAMPTON PL, COTO DE CAZA CA 92679
Kathryn Arnold director 1136 CHESTNUT AVE., WILMETTE IL 60091
Marvin Slosman director, officer: CEO and President 4 MENORAT HAMAOR ST., C/O INSPIREMD, INC., TEL AVIV L3 6744832
Isaac Blech director C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Agustin V Gago officer: EVP, Chief Commercial Officer 256 JERUSALEM AVE, MASSAPEQUA NY 11758
Eric L. Olson officer: VP of Global Sales Operations C/O INSPIREMD, INC., 800 BOYLSTON STREET, 16TH FLOOR, BOSTON MA 02199
Campbell Rogers director C/O INSPIREMD, INC., 800 BOYLSTON STREET, SUITE 16041, BOSTON MA 02199
James J Barry director C/O INSPIREMD, INC., 4 MENORAT HAMAOR ST., TEL AVIV L3 6744832
Eyal Weinstein director C/O LEOREX LTD., P.O.B. 15067 MATAM, HAIFA L3 31905

InspireMD (InspireMD) Headlines

From GuruFocus

InspireMD Announces Private Placement of Up to $113.6 Million

By sperokesalga sperokesalga 05-15-2023